Yissum - Research Development Company of the Hebrew University

Short Peptides Derived from GPCR that Selectively Modulate Signal Transduction for Vascular Disorders (Pro Angiogenic Molecules)

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cardiovascular, Peptide / Protein
Project ID : 7-2006-574

Description of the technology

Category

Life Sciences and Bio Technology

Keywords

G-protein coupled receptors

Application

One of the largest families of receptors in the human genome is that of the 7 transmembrane receptor (7-TMR) superfamily, also known as G-protein coupled receptors (GPCRs), numbering approximately 2000.

G-protein coupled receptors regulate a large number of important physiological processes. At least 40% of the prescription drugs that have been developed have actions related to these receptors. Most of these drugs work by interfering with the ligand binding to the receptor that occurs outside of cells. G-proteins are important effectors of cell activation

Our Innovation

The current technology is based on the discovery that compounds, comprising relatively short sequences of 5 to 20 amino acids, identical to native sequences appearing in a specific region of any of the 2nd loop of 7 transmembrane receptor are capable of altering the signal transduction mediated by the same 7TM receptor from which the sequences were obtained.

Technology

  • The technology covers a universal method for modulation (increase or decrease ) of the activity of any one of the 2000 G protein coupled receptors, comprising administration to the subject of a 5-20 amino acid peptide, preferably attached to a moiety for facilitating its entry to the cell. The invention covers literarily thousands of such p short peptides and their derivatives
  • Specific examples were obtained for several G-coupled receptors being: endothelial differentiation gene 3 (EDG3)- both for regulating angiogenesis and endothelia function, melanocortin 1 (MC1) and the β2-adrenoreceptor

Opportunity

  • The technology offers a universal method for treating any disease or pathological condition involving G-coupled receptor irregularity, by administration of very short amino acids sequences.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Shmuel Ben-Sasson
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.